The identification of safety and efficacy endpoints is a critical step in the development of any new drug. As we progress to first-in-man, it is critical that the validated assays for the measurement of soluble, cellular or tissue biomarker are robust, specific, sensitive, reproducible and efficient. These measurements assess the degree of safety or efficacy to a treatment and will ultimately drive decisions to dose(s), indication(s) and patient(s) selections.
Over the years, CIRION's scientists have gained expertise and knowledge in this area. The use of various technologies allows for appropriate analysis of small or large biomarker molecules. The 'fit-for-purpose' approach is used to biomarker assay development and validation.
- ELISA, ELISPOT, RIA and Binding Assay
- Single/multiplex assays with ECL technology/Meso Scale® platform
- Single/multiplex assays with xMAP technology/ Luminex® platform
- Immunophenotyping with Flow Cytometry
- Molecular Biology:
- Qualitative and Quantitative RT-PCR
- Viral quantification
CIRION has the experience and know-how to move your project to the next level.
These are only a few examples of what we can do.For more information, download our biomarkers list. If you have a special request, please contact us toll free at 1-866-688-2474 or by e-mail at firstname.lastname@example.org.